Earnings Call Summary | NeuroOne Medical(NMTC.US) Q1 2024 Earnings Conference
Earnings Call Summary | NeuroOne Medical(NMTC.US) Q1 2024 Earnings Conference
The following is a summary of the NeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcript:
以下是NeuroOne醫療技術公司（NMTC）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
NeuroOne reported a product revenue of $978,000 in Q1 2024, a significant increase from $115,000 in Q1 2023.
There was however a decline in collaboration revenue in Q1 2024 due to the absence of funds from the Zimmer Development Agreement that contributed $1,455,000 in Q1 2023.
Operating expenses and net loss saw an increase in Q1 2024 compared to the previous year, with a decrease in cash, cash equivalents, and short-term investments noted over the same period.
NeuroOne報告稱，2024年第一季度的產品收入爲97.8萬美元，較2023年第一季度的11.5萬美元大幅增長。
然而，由於齊默爾開發協議缺乏資金，2024年第一季度的合作收入有所下降，該協議在2023年第一季度貢獻了1,455,000美元。
與上年相比，2024年第一季度的運營支出和淨虧損有所增加，同期現金、現金等價物和短期投資有所減少。
Business Progress:
業務進展：
NeuroOne received FDA clearance for the OneRF Ablation System, with a limited commercial launch set for Q2 2024.
The company is exploring business partnerships for its OneRF System and potential application in pain treatment.
The Evolution sEEG electrode product line, in partnership with Zimmer Biomet, received positive feedback, with increased sales expected in future.
NeuroOne's Spinal Cord Stimulation Program showed progress in treating chronic back pain, and the company is entering contract discussions with a biotech company which may provide additional revenue by late 2024.
NeuroOne的OneRF消融系統獲得了美國食品藥品管理局的批准，定於2024年第二季度限量商用。
該公司正在探索其OneRF系統的業務合作伙伴關係以及在疼痛治療中的潛在應用。
與Zimmer Biomet合作推出的Evolution SeeG電極產品系列獲得了積極的反饋，預計未來的銷售額將增加。
NeuroOne的脊髓刺激計劃在治療慢性背痛方面取得了進展，該公司正在與一家生物技術公司進行合同討論，該公司可能會在2024年底之前提供額外收入。
More details: NeuroOne Medical IR
更多詳情： NeuroOne 醫療
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。